P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-05-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000936292.14792.3e |
| _version_ | 1797281377489518592 |
|---|---|
| author | D.E. Lowther E.A. Houseman G. Han E. Kleanthous D. Knoblock X. Zhou S. Banerjee S. Patel D. Figueroa |
| author_facet | D.E. Lowther E.A. Houseman G. Han E. Kleanthous D. Knoblock X. Zhou S. Banerjee S. Patel D. Figueroa |
| author_sort | D.E. Lowther |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:55:40Z |
| format | Article |
| id | doaj.art-1ab5a87505654a1e9698612a1bff1e23 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:55:40Z |
| publishDate | 2023-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-1ab5a87505654a1e9698612a1bff1e232024-03-03T03:59:02ZengWileyHemaSphere2572-92412023-05-017S2333410.1097/01.HS9.0000936292.14792.3e202305002-00060P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMAD.E. Lowther0E.A. Houseman1G. Han2E. Kleanthous3D. Knoblock4X. Zhou5S. Banerjee6S. Patel7D. Figueroa81 GSK, Stevenage, United Kingdom2 GSK, Upper Providence, PA, USA2 GSK, Upper Providence, PA, USA1 GSK, Stevenage, United Kingdom2 GSK, Upper Providence, PA, USA2 GSK, Upper Providence, PA, USA3 GSK, Bengaluru, India2 GSK, Upper Providence, PA, USA2 GSK, Upper Providence, PA, USAhttp://journals.lww.com/10.1097/01.HS9.0000936292.14792.3e |
| spellingShingle | D.E. Lowther E.A. Houseman G. Han E. Kleanthous D. Knoblock X. Zhou S. Banerjee S. Patel D. Figueroa P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA HemaSphere |
| title | P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_full | P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_fullStr | P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_full_unstemmed | P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_short | P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_sort | p41 no evidence of b cell maturation antigen bcma expression loss or systemic immune impairment after treatment with the bcma targeted antibody drug conjugate belantamab mafodotin in patients with relapsed refractory multiple myeloma |
| url | http://journals.lww.com/10.1097/01.HS9.0000936292.14792.3e |
| work_keys_str_mv | AT delowther p41noevidenceofbcellmaturationantigenbcmaexpressionlossorsystemicimmuneimpairmentaftertreatmentwiththebcmatargetedantibodydrugconjugatebelantamabmafodotininpatientswithrelapsedrefractorymultiplemyeloma AT eahouseman p41noevidenceofbcellmaturationantigenbcmaexpressionlossorsystemicimmuneimpairmentaftertreatmentwiththebcmatargetedantibodydrugconjugatebelantamabmafodotininpatientswithrelapsedrefractorymultiplemyeloma AT ghan p41noevidenceofbcellmaturationantigenbcmaexpressionlossorsystemicimmuneimpairmentaftertreatmentwiththebcmatargetedantibodydrugconjugatebelantamabmafodotininpatientswithrelapsedrefractorymultiplemyeloma AT ekleanthous p41noevidenceofbcellmaturationantigenbcmaexpressionlossorsystemicimmuneimpairmentaftertreatmentwiththebcmatargetedantibodydrugconjugatebelantamabmafodotininpatientswithrelapsedrefractorymultiplemyeloma AT dknoblock p41noevidenceofbcellmaturationantigenbcmaexpressionlossorsystemicimmuneimpairmentaftertreatmentwiththebcmatargetedantibodydrugconjugatebelantamabmafodotininpatientswithrelapsedrefractorymultiplemyeloma AT xzhou p41noevidenceofbcellmaturationantigenbcmaexpressionlossorsystemicimmuneimpairmentaftertreatmentwiththebcmatargetedantibodydrugconjugatebelantamabmafodotininpatientswithrelapsedrefractorymultiplemyeloma AT sbanerjee p41noevidenceofbcellmaturationantigenbcmaexpressionlossorsystemicimmuneimpairmentaftertreatmentwiththebcmatargetedantibodydrugconjugatebelantamabmafodotininpatientswithrelapsedrefractorymultiplemyeloma AT spatel p41noevidenceofbcellmaturationantigenbcmaexpressionlossorsystemicimmuneimpairmentaftertreatmentwiththebcmatargetedantibodydrugconjugatebelantamabmafodotininpatientswithrelapsedrefractorymultiplemyeloma AT dfigueroa p41noevidenceofbcellmaturationantigenbcmaexpressionlossorsystemicimmuneimpairmentaftertreatmentwiththebcmatargetedantibodydrugconjugatebelantamabmafodotininpatientswithrelapsedrefractorymultiplemyeloma |